TITLE

Are You Waiting to Inhale?

AUTHOR(S)
Weiger, Pamela; Whitfield, William; Farnsworth, Steve; Miller, Jacqueline; Moyer, Tina; Menninger Jr., Florian
PUB. DATE
April 2006
SOURCE
Diabetes Health;Apr2006, Vol. 15 Issue 4, p41
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Relates the opinions of diabetics in the U.S. on the market launching of Exubera, the noninjectible insulin from Pfizer Inc. Doubts concerning the drug; Consultation with an endocrinologist; Experience of a patient during a clinical trial on the drug.
ACCESSION #
20673953

 

Related Articles

  • Take a Deep Breath! Trecroci, Daniel // Diabetes Health;Apr2006, Vol. 15 Issue 4, p38 

    Weighs the benefits of the approval of Exubera, the noninjectible insulin drug developed by Pfizer Inc., to diabetics in the U.S. Results of clinical studies on Exubera; Mechanism of action and administration; Reaction of endocrinologists to the approval of the drug; Option of patients with type...

  • Is Exubera Another GlucoWatch?  // Diabetes Health;Apr2006, Vol. 15 Issue 4, p42 

    Relates the opinions of endocrinologists on the potential of Exubera, the noninjectible insulin from Pfizer Inc., to succeed in the U.S. market in 2006. Cost consideration; Possible effect of the drug's absorption issues; Comparison with the Food and Drug Administration approved GlucoWatch...

  • Inhaled insulin. Morton-Eggleston, Emma; Barrett, Eugene J. // BMJ: British Medical Journal (International Edition);5/6/2006, Vol. 332 Issue 7549, p1043 

    The article reports on the approval by the U.S. Food and Drug Administration of the first inhalable insulin preparation to treat types 1 and 2 diabetes melitus. The new drug is being marketed by drug manufacturer Pfizer. It comes in powder form that is made into an aerosol mechanically by a...

  • Pharma: Clinic Roundup.  // BioWorld Today;5/7/2012, Vol. 23 Issue 88, p2 

    This article reports on the failure of a Phase IIIb withdrawal design study conducted by Pfizer Inc. for Lyrica (pregabalin) in patients with diabetic peripheral neuropathy.

  • Can Newer Therapies Delay the Progression of Type 2 Diabetes Mellitus? Edward Horton // Endocrine Practice;Jul2008, Vol. 14 Issue 5, p625 

    Objective: To review the multifactorial and progressive nature of type 2 diabetes mellitus (T2DM), the consequences of its progression, and the potential of traditional and newer therapies to delay the progression of this disease.Methods: The relevant literature is reviewed, and the mechanisms...

  • Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections. Retnakaran, Ravi; Hochman, Jackie; DeVries, J. Hans; Hanaire-Broutin, Helene; Heine, Robert J.; Melki, Vincent; Zinman, Bernard // Diabetes Care;Nov2004, Vol. 27 Issue 11, p2590 

    OBJECTIVE -- Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. Thus, a comparison of efficacy between CSII...

  • Insulin Therapy in 2006. Garg, Satish K.; Dailey, George; Hirsch, Irl B. // Journal of Family Practice;Apr2006, Vol. 55 Issue 4, pS1 

    The article presents practical strategies for introducing insulin therapy. It provides the key points and recommendations for the treatment of diabetes through insulin and oral antidiabetic drugs (OADs). It presents the findings of the Diabetes Control and Complications Trial(DCCT) and the...

  • Type 2 diabetes: The role of basal insulin therapy. LeRoith, Derek; Levatan, Claresa S.; Hirsch, Irl B.; Riddle, Matthew C. // Journal of Family Practice;Mar2004, Vol. 53 Issue 3, p215 

    The efficiency and efficacy of adding basal insulin to existing oral antidiabetic agents, used against type-2 diabetes, was demonstrated in the randomized, open-label Treat-to-Target Trial. New evidence and methods continue to alter management of patients with type-2 diabetes. Appropriate...

  • For Type 2 Patients Requiring Basal Insulin Initiation, Insulin Detemir Offers the Flexibility of Once-Daily Dosing in the Morning or Evening: 3-Month Results from PREDICTIVEâ„¢. Gallwitz, Baptist; Trippe, Bruce; Zhang, Kezhou; Lüddeke, Hansjoachim // Diabetes;Jun2007 Supplement 1, Vol. 56, pA146 

    The article focuses on the findings of the PREDICTIVE study which assessed the efficacy of insulin detemir initiation on type 2 diabetic patients in the European cohort. The subjects were switched from oral antidiabetic drugs (OADs) alone to once-daily insulin detemir ± OADs treatment. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics